Summary
Medtronic plc (MDT) announced on March 30, 2023, through its indirect wholly owned subsidiary Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), the issuance of $2 billion in aggregate principal amount of senior notes. This offering comprises $1 billion of 4.250% Senior Notes due 2028 and $1 billion of 4.500% Senior Notes due 2033. The net proceeds, expected to be approximately $1.98 billion after expenses, are earmarked for the prepayment of a portion of Medtronic Luxco's Japanese-yen denominated term loan, which amounts to approximately $2.3 billion. This debt issuance represents a proactive move by Medtronic to refinance a specific tranche of its existing debt, likely to optimize its capital structure and potentially reduce interest expenses or alter its debt maturity profile. The notes are fully and unconditionally guaranteed by Medtronic plc and Medtronic, Inc., providing additional security to investors. While the offering itself is not expected to have a material impact on interest expense, net, it signifies ongoing financial management and debt servicing strategies by the company.
Key Highlights
- 1Medtronic Luxco issued $1 billion of 4.250% Senior Notes due 2028 and $1 billion of 4.500% Senior Notes due 2033, totaling $2 billion in debt.
- 2Net proceeds of approximately $1.98 billion are intended to prepay a portion of a ¥297 billion ($2.3 billion) Japanese-yen denominated term loan.
- 3The notes are general unsecured senior obligations of Medtronic Luxco, guaranteed by Medtronic plc and Medtronic, Inc.
- 4The 2028 Notes mature on March 30, 2028, and the 2033 Notes mature on March 30, 2033.
- 5Medtronic Luxco has the option to redeem the notes in whole or in part prior to their respective Par Call Dates at a premium, and at par on or after the Par Call Dates.
- 6The company expects the offering and use of proceeds to have an immaterial impact on net interest expense.
- 7This transaction is part of Medtronic's ongoing debt management and refinancing activities.